
Cocrystal Pharma, Inc. (NASDAQ:COCP – Free Report) – Investment analysts at Noble Financial issued their Q1 2027 EPS estimates for shares of Cocrystal Pharma in a report released on Tuesday, November 17th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings per share of ($0.17) for the quarter. The consensus estimate for Cocrystal Pharma’s current full-year earnings is ($0.69) per share. Noble Financial also issued estimates for Cocrystal Pharma’s Q2 2027 earnings at ($0.18) EPS, Q3 2027 earnings at ($0.17) EPS and Q4 2027 earnings at ($0.20) EPS.
COCP has been the topic of a number of other research reports. Weiss Ratings cut Cocrystal Pharma from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, August 21st. HC Wainwright reaffirmed a “buy” rating on shares of Cocrystal Pharma in a research note on Friday, October 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold”.
Check Out Our Latest Research Report on COCP
Cocrystal Pharma Stock Up 3.3%
Shares of Cocrystal Pharma stock opened at $1.01 on Wednesday. The business has a fifty day simple moving average of $1.07 and a 200 day simple moving average of $1.10. The stock has a market cap of $19.45 million, a PE ratio of -1.31 and a beta of 1.60. Cocrystal Pharma has a 12 month low of $0.76 and a 12 month high of $2.03.
Cocrystal Pharma (NASDAQ:COCP – Get Free Report) last announced its earnings results on Monday, November 16th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). The firm had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.10 million.
Cocrystal Pharma Company Profile
Cocrystal Pharma, Inc. is a biotechnology company focused on discovering and developing antiviral medicines. Its research targets viral proteins involved in replication, with the goal of developing treatments for infections including influenza, hepatitis C, norovirus and coronaviruses. The company uses structure-based drug discovery and computational methods to identify compounds that act on these viral targets. Its investigational programs have included candidates for influenza A and hepatitis C; these are research-stage medicines and are not approved treatments.
Recommended Stories
- Five stocks we like better than Cocrystal Pharma
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Cocrystal Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cocrystal Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
